Betul Oran1, Marcos de Lima. 1. Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: Relapse remains a major cause of treatment failure for acute myeloid leukemia (AML) patients treated with allogeneic hematopoietic stem cell transplantation (allo-HCT). Most patients that recur will perish due to low treatment efficacy, toxicity, or frailty issues. This review summarizes recent developments in clinical research and therapeutic applications for prevention and treatment of this complication of transplantation. RECENT FINDINGS: Several groups have demonstrated that monitoring minimal residual disease (MRD) after allo-HCT is feasible and is predictive of impending hematologic recurrence. The introduction of novel antileukemia agents in the preparative regimen, maintenance of remission treatment posttransplant, and early MRD-based therapeutic interventions all have the potential to improve outcomes. SUMMARY: Innovative basic and clinical investigation is urgently needed to improve treatment and prevention of AML recurrence after allogeneic transplantation.
PURPOSE OF REVIEW: Relapse remains a major cause of treatment failure for acute myeloid leukemia (AML) patients treated with allogeneic hematopoietic stem cell transplantation (allo-HCT). Most patients that recur will perish due to low treatment efficacy, toxicity, or frailty issues. This review summarizes recent developments in clinical research and therapeutic applications for prevention and treatment of this complication of transplantation. RECENT FINDINGS: Several groups have demonstrated that monitoring minimal residual disease (MRD) after allo-HCT is feasible and is predictive of impending hematologic recurrence. The introduction of novel antileukemia agents in the preparative regimen, maintenance of remission treatment posttransplant, and early MRD-based therapeutic interventions all have the potential to improve outcomes. SUMMARY: Innovative basic and clinical investigation is urgently needed to improve treatment and prevention of AML recurrence after allogeneic transplantation.
Authors: Marcos de Lima; David L Porter; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Christoph Schmid Journal: Biol Blood Marrow Transplant Date: 2013-09-07 Impact factor: 5.742
Authors: Gita Thanarajasingam; Haesook T Kim; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Philippe Armand Journal: Biol Blood Marrow Transplant Date: 2013-09-27 Impact factor: 5.742
Authors: T Ruutu; L C de Wreede; A van Biezen; R Brand; M Mohty; P Dreger; R Duarte; C Peters; L Garderet; S Schönland; A Gratwohl; D Niederwieser; T de Witte; N Kröger Journal: Bone Marrow Transplant Date: 2015-09-14 Impact factor: 5.483
Authors: Betül Oran; Jeff L Jorgensen; David Marin; Sa Wang; Sairah Ahmed; Amin M Alousi; Borje S Andersson; Qaiser Bashir; Roland Bassett; Genevieve Lyons; Julianne Chen; Katy Rezvani; Uday Popat; Partow Kebriaei; Keyur Patel; Gabriela Rondon; Elizabeth J Shpall; Richard E Champlin Journal: Haematologica Date: 2016-08-18 Impact factor: 9.941
Authors: Joshua M Jackson; James B Taylor; Małgorzata A Witek; Sally A Hunsucker; Jennifer P Waugh; Yuri Fedoriw; Thomas C Shea; Steven A Soper; Paul M Armistead Journal: Analyst Date: 2016-01-21 Impact factor: 4.616